LianBio Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
LianBio (LIANY) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.42 million as of 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2023-03-28
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.42M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.77M.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.33M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2022-12-31 | $2.42M 10-K · filed 2023-03-28 |
| 2021-12-31 | $1.77M 10-K · filed 2023-03-28 |
| 2020-12-31 | $1.33M 10-K · filed 2022-03-31 |